AIM Vaccine Co., Ltd. (6660.HK)

HKD 3.39

(-0.29%)

EBITDA Summary of AIM Vaccine Co., Ltd.

  • AIM Vaccine Co., Ltd.'s latest annual EBITDA in 2023 was -2.05 Billion CNY , down -121.0% from previous year.
  • AIM Vaccine Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -67.27 Million CNY , up 95.86% from previous quarter.
  • AIM Vaccine Co., Ltd. reported an annual EBITDA of -242.03 Million CNY in 2022, up 51.08% from previous year.
  • AIM Vaccine Co., Ltd. reported an annual EBITDA of -451.7 Million CNY in 2021, down -170.51% from previous year.
  • AIM Vaccine Co., Ltd. reported a quarterly EBITDA of -233.37 Million CNY for 2023 Q2, up 0.97% from previous quarter.
  • AIM Vaccine Co., Ltd. reported a quarterly EBITDA of -1.62 Billion CNY for 2023 Q4, down -596.44% from previous quarter.

Annual EBITDA Chart of AIM Vaccine Co., Ltd. (2023 - 2019)

Historical Annual EBITDA of AIM Vaccine Co., Ltd. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -2.05 Billion CNY -121.0%
2022 -242.03 Million CNY 51.08%
2021 -451.7 Million CNY -170.51%
2020 629.96 Million CNY 156.64%
2019 246.14 Million CNY 0.0%

Peer EBITDA Comparison of AIM Vaccine Co., Ltd.

Name EBITDA EBITDA Difference
Uni-Bio Science Group Limited 91.23 Million HKD 2349.289%
CK Life Sciences Int'l., (Holdings) Inc. 486.79 Million HKD 521.556%